You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 161 No. 8, April 23, 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (38)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Coagulation Disorders
 •Review
 •Venous Thromboembolism
 •Alert me on articles by topic

An Update on Hypercoagulable Disorders

Daniel G. Federman, MD; Robert S. Kirsner, MD

Arch Intern Med. 2001;161:1051-1056.

Venous thrombosis is a cause of considerable morbidity and is often responsible for chronic venous disorders that frequently lead to visits to dermatologists and others involved in wound healing. Over the past several years, many new causes of thrombophilia have been identified and have dramatically altered the approach to patients presenting with thrombosis. Newly described abnormalities associated with thrombophilia include the syndrome of activated protein C resistance, the prothrombin 20210A mutation, hyperhomocysteinemia, and elevated levels of coagulation factors VIII and XI. Clinicians can now frequently determine causes of thromboses that have previously been deemed idiopathic.


From the Department of Medicine, Yale University School of Medicine, New Haven, Conn, and Veterans Affairs Connecticut Health Care System, West Haven (Dr Federman); and Department of Dermatology and Cutaneous Surgery, Department of Epidemiology, University of Miami School of Medicine, Miami, Fla (Dr Kirsner).


RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(8):1120-1121.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Proteomic approaches to dissect platelet function: half the story
Gnatenko et al.
Blood 2006;108:3983-3991.
ABSTRACT | FULL TEXT  

Homozygosity in the Single Nucleotide Polymorphism Ser128Arg in the E-Selectin Gene Associated With Recurrent Venous Thromboembolism.
Jilma et al.
Arch Intern Med 2006;166:1655-1659.
ABSTRACT | FULL TEXT  

Review of Thrombophilic States
Beck and Berman
CLIN PEDIATR 2005;44:193-199.
 

Current and emerging treatment options for venous thrombosis: A case discussion
Haines and Nutescu
Am J Health Syst Pharm 2005;62:593-605.
FULL TEXT  

Locus-Specific Genetic Differentiation at Rw Among Warfarin-Resistant Rat (Rattus norvegicus) Populations
Kohn et al.
Genetics 2003;164:1055-1070.
ABSTRACT | FULL TEXT  

Screening for the Risk for Bleeding or Thrombosis
Eckman et al.
ANN INTERN MED 2003;138:W-15-W-24.
ABSTRACT | FULL TEXT  

The Risk of Recurrent Venous Thromboembolism in Heterozygous Carriers of Factor V Leiden and a First Spontaneous Venous Thromboembolism
Eichinger et al.
Arch Intern Med 2002;162:2357-2360.
ABSTRACT | FULL TEXT  

Laboratory thrombophilias and venous thromboembolism
Joffe and Goldhaber
Vasc Med 2002;7:93-102.
ABSTRACT  

Testing for Hypercoagulable Disorders
Ghobrial and Kwakwa
Arch Intern Med 2002;162:613-613.
FULL TEXT  

Timing of Hypercoagulable Screens
Kovacs et al.
Arch Intern Med 2002;162:613-614.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.